| Primary |
| Acute Myeloid Leukaemia |
23.5% |
| Hairy Cell Leukaemia |
16.2% |
| Langerhans' Cell Histiocytosis |
6.9% |
| Product Used For Unknown Indication |
6.5% |
| Febrile Neutropenia |
6.0% |
| Acute Myeloid Leukaemia Recurrent |
5.7% |
| Mantle Cell Lymphoma |
5.6% |
| Multiple Sclerosis |
5.4% |
| Chronic Lymphocytic Leukaemia |
5.1% |
| B-cell Lymphoma |
2.8% |
| Prophylaxis |
2.8% |
| Waldenstrom's Macroglobulinaemia |
2.8% |
| Immunosuppression |
2.0% |
| Angioimmunoblastic T-cell Lymphoma |
1.5% |
| Systemic Mastocytosis |
1.5% |
| Acute Lymphocytic Leukaemia |
1.2% |
| Multiple Sclerosis Relapse |
1.2% |
| Plasma Cell Myeloma |
1.2% |
| Antifungal Prophylaxis |
1.1% |
| Anti-infective Therapy |
0.9% |
|
| Thrombocytopenia |
12.7% |
| Pyrexia |
10.2% |
| Rash Maculo-papular |
10.2% |
| Lymphopenia |
9.3% |
| Off Label Use |
7.6% |
| Bone Marrow Failure |
5.1% |
| Pancytopenia |
4.2% |
| Pneumonia |
4.2% |
| Aspergillosis |
3.4% |
| Haemorrhage |
3.4% |
| Myelodysplastic Syndrome |
3.4% |
| Neutropenia |
3.4% |
| Thyroiditis |
3.4% |
| Toxicity To Various Agents |
3.4% |
| Type Iv Hypersensitivity Reaction |
3.4% |
| Dermatitis |
2.5% |
| Hairy Cell Leukaemia |
2.5% |
| Incorrect Route Of Drug Administration |
2.5% |
| Neoplasm Malignant |
2.5% |
| Pulmonary Haemorrhage |
2.5% |
|
| Secondary |
| Chronic Lymphocytic Leukaemia |
15.8% |
| Multiple Sclerosis |
8.2% |
| Langerhans' Cell Histiocytosis |
6.6% |
| Product Used For Unknown Indication |
6.6% |
| Chronic Obstructive Pulmonary Disease |
5.6% |
| Prophylaxis |
5.4% |
| Nasopharyngitis |
5.2% |
| Infection Prophylaxis |
4.5% |
| Mantle Cell Lymphoma |
4.5% |
| Seasonal Allergy |
4.5% |
| Fungal Infection |
4.5% |
| Pain |
3.8% |
| Micrographic Skin Surgery |
3.7% |
| Oropharyngeal Pain |
3.7% |
| Acute Monocytic Leukaemia |
3.5% |
| B-cell Lymphoma |
3.3% |
| Constipation |
2.8% |
| Multiple Sclerosis Relapse |
2.7% |
| Depression |
2.7% |
| Influenza Like Illness |
2.4% |
|
| Pneumonia |
17.3% |
| Anaemia Haemolytic Autoimmune |
10.6% |
| Autoimmune Thrombocytopenia |
8.7% |
| Myelodysplastic Syndrome |
6.3% |
| Thrombocytopenia |
6.3% |
| Sepsis |
5.8% |
| Grand Mal Convulsion |
5.3% |
| Pancytopenia |
4.8% |
| Chronic Lymphocytic Leukaemia Transformation |
4.3% |
| Oesophageal Carcinoma |
4.3% |
| Stomatitis |
3.8% |
| Neutrophil Count Decreased |
3.4% |
| Squamous Cell Carcinoma |
3.4% |
| Hypoxia |
2.9% |
| Lung Neoplasm Malignant |
2.9% |
| Non-small Cell Lung Cancer |
2.4% |
| Drug Eruption |
1.9% |
| Febrile Neutropenia |
1.9% |
| Neutropenia |
1.9% |
| Off Label Use |
1.9% |
|
| Concomitant |
| Product Used For Unknown Indication |
18.0% |
| Drug Use For Unknown Indication |
17.2% |
| Lymphoma |
11.7% |
| Hairy Cell Leukaemia |
8.6% |
| Chemotherapy |
5.5% |
| Coeliac Disease |
4.2% |
| B-cell Lymphoma |
3.6% |
| Diffuse Large B-cell Lymphoma |
3.6% |
| Bone Marrow Conditioning Regimen |
3.1% |
| Non-hodgkin's Lymphoma |
3.1% |
| Mantle Cell Lymphoma |
2.9% |
| Stem Cell Transplant |
2.9% |
| Multiple Sclerosis |
2.6% |
| Acute Myeloid Leukaemia |
2.1% |
| Follicle Centre Lymphoma, Follicular Grade I, Ii, Iii Stage Iv |
2.1% |
| Haematopoietic Stem Cell Mobilisation |
2.1% |
| Pneumonia |
2.1% |
| Graft Versus Host Disease |
1.6% |
| Prophylaxis |
1.6% |
| Pyrexia |
1.6% |
|
| Malignant Neoplasm Progression |
9.5% |
| Progressive Multifocal Leukoencephalopathy |
9.5% |
| Neutropenia |
8.1% |
| Disease Progression |
6.8% |
| Fungal Sepsis |
5.4% |
| Nervous System Disorder |
5.4% |
| Pancytopenia |
5.4% |
| Sepsis |
5.4% |
| Tumour Lysis Syndrome |
5.4% |
| White Blood Cell Count Decreased |
5.4% |
| Drug Ineffective |
4.1% |
| Encephalitis |
4.1% |
| Intestinal T-cell Lymphoma |
4.1% |
| Respiratory Failure |
4.1% |
| Visual Impairment |
4.1% |
| Bone Marrow Failure |
2.7% |
| Hepatic Failure |
2.7% |
| Osteoporosis |
2.7% |
| Pain In Extremity |
2.7% |
| Rash Erythematous |
2.7% |
|
